Lonsurf Hits Phase III OS Target In Gastric Cancer Study

10 May 2018

• By John Davis

An improvement in overall survival seen in the Phase III TAGS study and a unique mechanism of action augurs well for Taiho/Servier's Lonsurf gaining gastric cancer as an additional indication, but future competitive pressures are likely to be intense in this therapeutic sector.

Helicobacter pylori — H pylori infection may precede the development of stomach cancer • Source: Shutterstock

French multinational Servier SA, may have moved a step closer to realizing its ambitions in oncology with positive top-line results emerging from the pivotal Phase III TAGS study, that is evaluating the oral anticancer therapy, Lonsurf (trifluridine plus tipiracil), in patients with gastric cancer. But research into better therapies for gastric cancer is intense, so future success is not a foregone conclusion.

Servier and the Otsuka subsidiary, Taiho Pharmaceutical Co. Ltd., are collaborating on the further development of Lonsurf, currently marketed for the treatment of metastatic colorectal cancer, and the companies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Angelini Advances Brain Health Ambitions With GRIN Pact

27 May 2025

• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

27 May 2025

• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

26 May 2025

• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

26 May 2025

• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

26 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.